Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Lymphoma 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Lymphoma, Large B-Cell, Diffuse 18Lymphoma, Non-Hodgkin 17Neuroblastoma 16Leukemia, Myeloid, Acute 14Leukemia 13Hodgkin Disease 13Central Nervous System Neoplasms 13Small Cell Lung Carcinoma 10Sarcoma 9Brain Neoplasms 9Recurrence 8Medulloblastoma 8Leukemia, Lymphocytic, Chronic, B-Cell 8Rhabdoid Tumor 7Multiple Myeloma 7Lymphoma, B-Cell 7Lung Neoplasms 7Burkitt Lymphoma 7Lymphoma, Mantle-Cell 6Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Follicular 6Lymphoma, B-Cell, Marginal Zone 6Astrocytoma 6Teratoma 5Ovarian Neoplasms 5Neoplasms, Germ Cell and Embryonal 5Neoplasms 5Glioma 5

Interventions

Trastuzumab 597Paclitaxel 562Cyclophosphamide 545Docetaxel 479Capecitabine 388Letrozole 350Fulvestrant 311Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 177Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × etoposide phosphate × Clear all
NCT00810017 2022-05-19

Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer

Medstar Health Research Institute

Phase 2 Terminated
2 enrolled 3 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00020722 2016-02-17

Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer

Barbara Ann Karmanos Cancer Institute

Phase 2 Terminated
7 enrolled 3 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡